Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Nab-paclitaxel/danburstotug complex AP160

A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, complexed with danburstotug, a human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic activity. Upon administration of nab-paclitaxel/danburstotug complex AP160, the danburstotug moiety specifically binds to PD-L1 and targets this formulation to PD-L1-positive tumor cells. In turn, paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of PD-L1-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and targeting by the danburstotug moiety allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types.
Synonym:Nab-paclitaxel/STI-3031 complex AP160
Code name:AP 160
AP-160
AP160
Search NCI's Drug Dictionary